Candriam S.C.A. Sells 99,148 Shares of Definium Therapeutics, Inc. $DFTX

Candriam S.C.A. trimmed its holdings in Definium Therapeutics, Inc. (NASDAQ:DFTX) by 16.1% in the third quarter, Holdings Channel reports. The fund owned 515,277 shares of the company’s stock after selling 99,148 shares during the period. Candriam S.C.A.’s holdings in Definium Therapeutics were worth $19,683,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Wellington Management Group LLP acquired a new stake in shares of Definium Therapeutics during the second quarter worth about $138,755,000. Seven Fleet Capital Management LP bought a new stake in Definium Therapeutics during the 2nd quarter worth approximately $6,992,000. Moody Aldrich Partners LLC raised its holdings in Definium Therapeutics by 191.8% during the 3rd quarter. Moody Aldrich Partners LLC now owns 148,870 shares of the company’s stock worth $5,666,000 after buying an additional 97,845 shares during the period. Alps Advisors Inc. raised its holdings in Definium Therapeutics by 61.3% during the 3rd quarter. Alps Advisors Inc. now owns 178,006 shares of the company’s stock worth $6,775,000 after buying an additional 67,618 shares during the period. Finally, TD Waterhouse Canada Inc. acquired a new stake in shares of Definium Therapeutics during the second quarter worth $1,592,000. 27.91% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on DFTX. UBS Group reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Definium Therapeutics in a research report on Tuesday, September 15th. Maxim Group set a $55.00 target price on Definium Therapeutics and gave the stock a “buy” rating in a report on Friday, August 14th. Robert W. Baird lifted their price target on Definium Therapeutics from $75.00 to $79.00 and gave the company an “outperform” rating in a research note on Tuesday, September 15th. Wall Street Zen downgraded Definium Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Definium Therapeutics in a report on Monday, September 14th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Definium Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $66.00.

Definium Therapeutics Stock Performance

NASDAQ:DFTX opened at $33.27 on Monday. The company has a market cap of $4.47 billion, a P/E ratio of -9.70 and a beta of 2.23. Definium Therapeutics, Inc. has a twelve month low of $10.46 and a twelve month high of $49.70. The business has a 50 day moving average price of $36.60 and a two-hundred day moving average price of $29.95. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). As a group, analysts expect that Definium Therapeutics, Inc. will post -3.08 EPS for the current fiscal year.

Insider Buying and Selling at Definium Therapeutics

In other Definium Therapeutics news, insider Matthew T. Wiley sold 3,097 shares of Definium Therapeutics stock in a transaction on Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $113,257.29. Following the sale, the insider directly owned 359,036 shares in the company, valued at approximately $13,129,946.52. The trade was a 0.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Barrow sold 31,550 shares of Definium Therapeutics stock in a transaction on Friday, September 25th. The shares were sold at an average price of $36.57, for a total transaction of $1,153,783.50. Following the completion of the sale, the chief executive officer owned 2,213,090 shares in the company, valued at $80,932,701.30. The trade was a 1.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 71,098 shares of company stock worth $2,626,115. Company insiders own 2.40% of the company’s stock.

Definium Therapeutics Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.